Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Diagnosis of diffuse intrinsic pontine glioma (DIPG) for decades has relied on imaging
studies and clinical findings. Histologic confirmation has been absent with surgical biopsy
of brainstem tumors not believed to have acceptable safety. The prognosis of DIPG has
remained quite poor and novel therapeutic strategies are needed. This DIPG Biology and
Treatment Study (DIPG-BATS) study incorporates a surgical biopsy at presentation using strict
preoperative neurosurgical planning and stratifies participants to receive FDA-approved
agents chosen on the basis of specific biologic targets. This is the first prospective
national clinical trial to examine the feasibility and safety of incorporating surgical
biopsy into potential treatment strategies for children with DIPG.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute Karen D. Wright MD
Collaborators:
Ann & Robert H Lurie Children's Hospital of Chicago Boston Children's Hospital Boston Children’s Hospital Children's Healthcare of Atlanta Children's Hospital Colorado Children's Hospital Los Angeles Children's Hospital of Michigan Children's Hospitals and Clinics of Minnesota Children's National Research Institute Cook Children's Medical Center Doernbecher Children's Hospital Duke University Johns Hopkins University Lucile Packard Children's Hospital Medical University of South Carolina Milton S. Hershey Medical Center Nemours Children's Clinic Nemours Children's Clinic Jacksonville New York University Nicklaus Children's Hospital f/k/a Miami Children's Hospital OHSU Doernbecher Children's Hospital Phoenix Children's Hospital Seattle Children's Seattle Children's Hospital University of California, San Francisco University of Louisville UT Southwestern Medical Center Washington University School of Medicine